All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

The most important comorbidity associated with chronic obstructive pulmonary disease (COPD), due to its impact on prognosis and mortality, is cardiovascular disease (CVD).\[[@pone.0152987.ref001]--[@pone.0152987.ref002]\] In this setting, previous studies suggest that COPD subjects have an increased risk of ischemic heart disease independent of smoking, age or gender.\[[@pone.0152987.ref003]--[@pone.0152987.ref005]\] However, the underlying mechanisms of this frequent association (between COPD and CVD) have not been completely elucidated.\[[@pone.0152987.ref004]\] Although the pathogenesis of atherosclerosis is complex, low-grade systemic inflammation, which is present in COPD and in CVD, could be one of the centrepiece events leading to systemic vascular remodelling and plaque formation.\[[@pone.0152987.ref003]\] Moreover, the remodelling of pulmonary vessels is a well-recognized finding in COPD.\[[@pone.0152987.ref006]--[@pone.0152987.ref007]\] This process is characterized by the migration and proliferation of vascular smooth muscle cells, inducing intimal hyperplasia and, therefore, subsequent luminal narrowing.\[[@pone.0152987.ref007]\] These pulmonary changes are mainly caused by sustained inflammatory process triggered by smoke exposure.\[[@pone.0152987.ref008]\]

However, to date, to the best of our knowledge, no previous histological study has evaluated vascular remodelling changes, such as the intimal thickening of the systemic arteries of COPD subjects, and its relationship with the presence of pulmonary intimal hyperplasia. The principal aim of study was to determine differences in intimal thickening in terms of the percentage of intimal area (%IA) of systemic arteries in COPD subjects and smokers. Secondary aims include an evaluation of differences in other intimal thickening parameters, all parameter comparisons with a non-smoker group, the determination of the variables associated with systemic and pulmonary intimal thickening and an evaluation of the correlation between systemic and pulmonary changes in the overall population.

Methods {#sec006}
=======

Population {#sec007}
----------

This was a prospective investigation, conducted in consecutive subjects who required lung resection for the treatment of lung cancer recruited from the Department of Pulmonary Medicine of University Hospital of Bellvitge (L'Hospitalet de Llobregat, Spain). Demographic and clinical data were obtained from patients' medical records. A preoperative pulmonary function test was performed in all subjects. Patients were divided into three groups according to their smoking history and pulmonary function tests: 1) COPD subjects (all of whom were current or former smokers with airflow limitation), 2) smokers (current or former smokers with normal lung function), and 3) non-smokers (never-smokers). Exclusion criteria were the presence of any pulmonary disease other than COPD and previous treatment with chemotherapy or radiotherapy regimens or previous lung surgery. The definition of COPD was established following the current guidelines.\[[@pone.0152987.ref001]\] The study was approved by the local ethics committee "Comitè Ètic d' Investigació Clínica del Hospital de Bellvitge, N° PR006/11", and performed in accordance with the Declaration of Helsinki. All patients signed an informed consent form.

Sample collection {#sec008}
-----------------

To evaluate systemic circulation, sections of the 5th posterior intercostal (IC) artery (1--1.5cm in length) were taken during the thoracotomy incision. To assess pulmonary circulation, lung samples were obtained from the piece of lung resection, as far away as possible from the tumour, and muscular pulmonary arteries with an external diameter between 100 to 500 μm were considered in the analyses. Both tissues (IC artery and lung samples) were fixed overnight in 4% paraformaldehyde following established methods of fixation and preparation of samples for morphometry.\[[@pone.0152987.ref009]\] Venous blood samples were collected from all subjects. Fasting blood glucose (FBG), total cholesterol, triglycerides, high-density lipoprotein cholesterol (cHDL), low-density lipoprotein cholesterol (cLDL), and blood cell counts were determined with standard laboratory methods. Metabolic syndrome (MetS) was defined as the presence of three or more of the metabolic parameters in accordance with current criteria as detailed in [S1 File](#pone.0152987.s001){ref-type="supplementary-material"}.\[[@pone.0152987.ref010]\]

Morphometric analysis {#sec009}
---------------------

Tissue sections were stained with elastin-orcein stain to localize elastin fibres and to differentiate the external elastic lamina (EEL) and internal elastic lamina (IEL) from all arteries ([Fig 1A](#pone.0152987.g001){ref-type="fig"}). Only vessels with complete elastic laminas were evaluated. Using a digital micro-imaging device (Leica DMD108, Leica Microsystems GmbH- Germany), EEL and IEL and the inner aspect of the intimae were outlined as previously described \[[@pone.0152987.ref009]\] by two different observers working blindly with regard to the study groups. In addition, artery diameters and areas of lumen, IEL, intimal and medial layer were calculated ([Fig 1B](#pone.0152987.g001){ref-type="fig"}). In order to evaluate the effect of vascular contraction and tissue shrinkage during manipulation or fixation, an index of narrowing was estimated for each artery ([S1 File](#pone.0152987.s001){ref-type="supplementary-material"}).\[[@pone.0152987.ref011]\] In line with previous studies of vascular remodelling and atherosclerosis and following stereological methods for vascular evaluation,\[[@pone.0152987.ref009], [@pone.0152987.ref012]--[@pone.0152987.ref013]\] four methods were used to analyze the degree of intimal thickening: 1) percentage of intimal area (%IA = 100Xintimal area/measured total area or area encompassed by the EEL), 2) percentage of luminal narrowing (%LN = 100Xintimal area/IEL area) which consider IEL as the surface reference, 3) intimal thickness index (ITI = intimal area/medial area), and 4) intima-to-media ratio (IMR = width of intima at maximal intimal thickness/width of media at maximal intimal thickness).

![Histologic and morphometric analyses.\
**A.** Fifth intercostal artery showing almost no intimal thickness and muscular media layer. Note also the absence of elastic laminas except for the internal elastic lamina (IEL) and external elastic lamina (EEL). **B**. Methods used for morphometric analyses as described in the text. A solid white line represents the IEL and the discontinuous black line shows the EEL. The area enclosed by the solid black line is the lumen area (LA), the area enclosed by the solid white line is the combined lumen + intima area (IA) and the area enclosed by the discontinuous black line is the lumen + intima + media area (MA). A double-headed black arrow represents maximal intimal thickness (Max.It). The double-headed white arrow shows the medial thickening (Mt) at maximal intimal thickness. Elastin-orcein stain, scale bar = 100μm.](pone.0152987.g001){#pone.0152987.g001}

Study endpoints and sample size calculation {#sec010}
-------------------------------------------

The primary endpoint of this study was the difference in the %IA of systemic arteries in COPD patients compared to smokers. Assuming a standard deviation of 5(%), a sample size of 12 subjects per group was needed to detect a minimal difference between groups of 6%; with 80% power and a two-tailed p-value less than 0.05. Considering an approximate 20% dropout rate (e.g. inadequate samples for morphometric measurements), the inclusion of 15 subjects by group was allowed to ensure that data from 12 patients was available for analysis. Secondary endpoints included: 1) between-group comparisons for %LN, ITI and IMR of systemic arteries, 2) all parameter comparisons with a non-smoker group, 3) associations between clinical variables and %IA of systemic and pulmonary arteries, and 4) correlations between systemic and pulmonary remodelling parameters in the overall population.

Statistical methods {#sec011}
-------------------

For baseline characteristics, continuous variables were expressed as mean±SD or by median and interquartile range, whether a normal distribution was assumed or not (Kolmogorov-Smirnov test), respectively. Comparisons of continuous variables were performed with the Student's t-test or Mann-Whitney's U test as appropriate, while qualitative variables were compared with the chi-square test or Fisher's exact test (if the expected cell frequencies were lower than 5). An ANOVA method with a general linear model (GLM) was used to evaluate overall comparisons. The primary endpoint (difference in the %IA of systemic arteries in COPD patients compared to smokers), and all other between-groups comparisons were performed using the least significant difference method with GLM. All adjusted analyses were performed with an ANCOVA method by GLM, using as covariates those variables associated with %IA in the overall population of the study (p\<0.10): gender, MetS, cHDL and circulating leukocytes. Results are reported as least squares means (LSM) ± standard error of the mean (SEM) for the analyses detailed above. The linear regression analyses performed to determine which clinical factors were associated with the intimal thickening of systemic and pulmonary vessels are detailed in [S1 File](#pone.0152987.s001){ref-type="supplementary-material"}. Spearman's correlation coefficients (p) were used to assess the relationships between pairs of continuous intimal thickening parameters in systemic and pulmonary arteries. A two-tailed p-value of \<0.05 was considered as statistically significant in all the tests performed. Statistical analysis was performed using PASW Statistics v18.0 software (SPSS Inc., Chicago, IL).

Results {#sec012}
=======

Consecutive samples from 48 patients undergoing lung resection surgery were prospectively included in this protocol. However, six of them (12.5%) were excluded due to poor conservation of vessel architecture (n = 4) or incomplete measurable elastic laminas despite several attempts at the reorientation of the sample (n = 2).Therefore, 42 subjects with valid IC arteries were analysed. Seventeen in the group of COPD (current = 11 and former smokers = 6), 14 in the smokers group (current = 5 and former smokers = 9), and 11 in the non-smokers group. Overall, baseline variables were mostly well balanced between groups (data is summarized in [Table 1](#pone.0152987.t001){ref-type="table"}). However, some differences were observed in the COPD group compared to smokers, where higher tobacco consumption (pack-years) was observed in COPD group, and a higher prevalence of metabolic syndrome and diabetes mellitus was seen in smokers. In the comparisons performed with the non-smokers group, predominance of male gender and the presence of aortic calcifications in the COPD and smokers groups were observed.

10.1371/journal.pone.0152987.t001

###### Baseline demographics by groups.

![](pone.0152987.t001){#pone.0152987.t001g}

  Parameters                     COPD (N = 17)                                                                                        Smokers (N = 14)       Non smokers (N = 11)    Overall p-value
  ------------------------------ ---------------------------------------------------------------------------------------------------- ---------------------- ----------------------- -----------------
  Male gender, n (%)             16 (94.1)[^†^](#t001fn002){ref-type="table-fn"}                                                      13 (92.9)              4 (36.4)                \<0.001
  Age, years                     63.4 \[57.7--68.8\]                                                                                  58.3 \[50.0--65.9\]    66.1 \[49.5--68.9\]     0.524
  BMI, kg/m^2^                   24.0 \[21.7--27.7\]                                                                                  27.1 \[25.0--30.4\]    28.9 \[21.5--30.1\]     0.187
  Pack-years                     45 \[39--60\][^†^](#t001fn002){ref-type="table-fn"}^,^[^‡^](#t001fn003){ref-type="table-fn"}         37.5 \[20--41.3\]      0 \[0--0\]              \<0.001
  Current smoking, n (%)         11 (64.7)[^†^](#t001fn002){ref-type="table-fn"}                                                      5 (35.7)               0                       0.003
  Emphysema in CT, n (%)         12 (70.6)[^†^](#t001fn002){ref-type="table-fn"}^,^[^‡^](#t001fn003){ref-type="table-fn"}             4 (28.6)               0                       0.001
  Aortic calcifications, n (%)   13 (76.5)[^†^](#t001fn002){ref-type="table-fn"}                                                      8 (57.1)               3 (27.3)                0.037
  Systemic hypertension, n (%)   5 (29.4)                                                                                             7 (50.0)               4 (36.4)                0.497
  Diabetes Mellitus, n (%)       1 (5.9)[^‡^](#t001fn003){ref-type="table-fn"}                                                        7 (50)                 0                       0.001
  Renal failure, n (%)           0                                                                                                    0                      0                       \-
  Met.S, n (%)                   6 (35.3)[^‡^](#t001fn003){ref-type="table-fn"}                                                       11 (78.6)              3 (27.3)                0.016
  Lipid lowering, n (%)          5 (29.4)                                                                                             5 (35.7)               3 (27.3)                0.888
  ACEIs/ARBs, n (%)              5 (29.4)                                                                                             8 (57.1)               3 (27.3)                0.198
  FEV~1~ Post-BD, % predicted    62.0 \[53.9--82.0\][^†^](#t001fn002){ref-type="table-fn"}^,^[^‡^](#t001fn003){ref-type="table-fn"}   97.7 \[80.0--103.5\]   107.0 \[89.3--119.8\]   \<0.001
  FEV~1~/FVC Post-BD, %          54.9 \[43.3--67.6\][^†^](#t001fn002){ref-type="table-fn"}^,^[^‡^](#t001fn003){ref-type="table-fn"}   76.3 \[72.6--81.2\]    77.2 \[73.7--81.5\]     \<0.001
  D~LCO~, % predicted            68.3 \[53.0--76.5\][^†^](#t001fn002){ref-type="table-fn"}^,^[^‡^](#t001fn003){ref-type="table-fn"}   87.1 \[71.5--102.3\]   84.4 \[72.1--103\]      0.001
  LABA, n (%)                    6 (35.3)[^‡^](#t001fn003){ref-type="table-fn"}                                                       \-                     \-                      0.006
  Inhaled CS, n (%)              5 (29.4)[^‡^](#t001fn003){ref-type="table-fn"}                                                       \-                     \-                      0.015
  WC, cm                         83.1 \[76.3--93.8\]                                                                                  90.9 \[86.5--95.7\]    88.4 \[78.4--99.1\]     0.299
  SBP, mmHg                      130 \[120--137\]                                                                                     130 \[121--138\]       126 \[120--135\]        0.835
  DBP, mmHg                      73 \[70--82\]                                                                                        74 \[70--79\]          70 \[60--78\]           0.340
  cHDL, mmol/L                   1.23 \[0.90--1.37\][^†^](#t001fn002){ref-type="table-fn"}                                            1.19 \[0.78--1.37\]    1.55 \[1.18--2.07\]     0.030
  cLDL, mmol/L                   2.51 \[1.91--3.19\]                                                                                  2.26 \[1.23--3.05\]    2.96 \[2.24--3.50\]     0.187
  Total cholesterol, mmol/L      4.41 \[3.68--5.03\]                                                                                  4.44 \[3.70--4.99\]    5.55 \[3.88--5.86\]     0.516
  Triglycerides, mmol/L          1.25 \[0.83--1.86\]                                                                                  1.99 \[1.61--2.39\]    1.60 \[1.17--1.88\]     0.131
  FBG, mmol/L                    5.6 \[4.8--6.6\]                                                                                     6.7 \[5.2--7.5\]       5.4 \[4.9--6.5\]        0.074
  Leukocytes count, x10E9/L      8.2 \[7.7--9.9\][^†^](#t001fn002){ref-type="table-fn"}                                               7.8 \[6.8--8.8\]       6.3 \[5.7--8.3\]        0.045

Data are presented as median \[25^th^-75^th^ percentile\]. BMI: body mass index, Met.S: Metabolic syndrome, ACEIs/ARBs: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, FEV~1~: forced expiratory volume in one second, BD: bronchodilator, FVC: forced vital capacity, D~LCO~: diffusing capacity of the lungs for carbon monoxide, LABA: long acting β-agonists, CS: inhaled corticosteroids, WC: waist circumference; SBP: systolic blood pressure, DBP: diastolic blood pressure, cHDL: high-density lipoprotein cholesterol, cLDL: low-density lipoprotein cholesterol, FBG: fasting blood glucose.

^†^ means a p-value \<0.05 for the difference between COPD and non-smokers group, and

^‡^ means a p-value \<0.05 for the difference between COPD and smokers group.

Morphometric measurements and severity indices of intimal thickening {#sec013}
--------------------------------------------------------------------

Morphometric measurements of systemic arteries showed no differences in the dimensions of vessels or areas between groups ([Table 2](#pone.0152987.t002){ref-type="table"}). The severity indices of intimal thickening as evaluated by non-adjusted analyses (%IA, %LN, ITI and IMR) were not significantly different between COPD and smokers. However, in the adjusted analysis %IA was significantly higher in COPD subjects compared to smokers. %LN and ITI showed a numerically increasing trend in the COPD group compared to the smokers group, while not attaining statistical significance. Three of the four indices of intimal thickening (%IA, %LN and ITI) were significantly higher in the COPD group than in the group of non-smokers. Covariates included in the adjusted analyses were gender, MetS, cHDL and circulating leukocytes. Individual data and p-values of unadjusted and adjusted analysis of intimal thickening parameters by groups are represented in [Fig 2A--2D](#pone.0152987.g002){ref-type="fig"}. No severe lesions with calcification were observed in the arteries examined.

![Severity indices of intimal thickening in systemic and pulmonary vessels, by groups.\
**A-D** represents individual data of systemic intimal thickening parameters: intimal area, luminal narrowing, intimal thickness index and intima-to-media ratio, respectively. **E-H** represents individual data of pulmonary intimal thickening parameters: intimal area, luminal narrowing, intimal thickness index and intima-to-media ratio, respectively. Horizontal bars indicate least squares mean values. P values for the pairwise comparisons using the least significant difference method with general linear model. P1: P-value for unadjusted analysis, P2: P-value for adjusted analysis using as covariables: gender, MetS, cHDL and circulating leukocytes.](pone.0152987.g002){#pone.0152987.g002}

10.1371/journal.pone.0152987.t002

###### Morphometric measurements and severity indices of intimal thickening in systemic and pulmonary arteries by groups.

![](pone.0152987.t002){#pone.0152987.t002g}

  ------------------------------------------------------------ ----------------------------------------------------------- ------------------------ ------------------------ --------------------
  **Measurements**                                             **Systemic arteries**                                                                                         
  **COPD**                                                     **Smokers**                                                 **Non smokers**          **Overallp-value**       
  Measured external diameter, μm                               557 \[485--668\]                                            506 \[440--599\]         505 \[427--632\]         0.385
  Measured total area, mm^-2^x10^-3^                           239 \[162--337\]                                            199 \[143--254\]         189 \[141--277\]         0.338
  Index of narrowing[^a^](#t002fn004){ref-type="table-fn"}     0.27 \[0.24--0.33\]                                         0.30 \[0.23--0.34\]      0.28 \[0.27--0.32\]      0.845
  Lumen area, mm^-2^x10^-3^                                    49.9 \[25.9--69.6\]                                         47.4 \[24.5--59.2\]      58.8 \[20.1--92.2\]      0.811
  Intima area, mm^-2^x10^-3^                                   32.0 \[19.6--57.0\]                                         26.8 \[17.7--37.7\]      23.4 \[17.5--37.1\]      0.327
  Muscular area, mm^-2^x10^-3^                                 157.2 \[115.5--201.9\]                                      117.1 \[96.4--161.1\]    113.3 \[72.9--164.8\]    0.169
  **Severity Indices**[^b^](#t002fn005){ref-type="table-fn"}                                                                                                                 
  \% intimal area                                              15.6 ± 1.5^†,^[^‡^](#t002fn003){ref-type="table-fn"}        14.2 ± 1.6               13.1 ± 1.8               0.022
  \% luminal narrowing                                         44.9 ± 4.2^†^                                               40.2 ± 4.7               36.9 ± 5.3               0.030
  Intimal thickness index                                      0.25 ± 0.03^†^                                              0.24 ± 0.03              0.21 ± 0.03              0.091
  Intima to media ratio                                        0.46 ± 0.04                                                 0.46 ± 0.05              0.37 ± 0.05              0.678
                                                               **Pulmonary arteries**                                                                                        
                                                               **COPD**                                                    **Smokers**              **Non smokers**          **Overallp-value**
  N° of arteries measured by patient                           10.2 ± 1.2                                                  13.2 ± 1.8               8.7 ± 2.3                0.212
  Measured external diameter, μm                               294.2 \[256.2--362.1\]                                      323.9 \[303.5--406.4\]   327.5 \[314.8--360.1\]   0.176
  Measured total area, mm^-2^x10^-3^                           64.0 \[49.8--99.1\]                                         77.4 \[64.2--121.6\]     74.3 \[65.8--84.7\]      0.237
  Index of narrowing[^a^](#t002fn004){ref-type="table-fn"}     0.30 \[0.28--0.32\]                                         0.31 \[0.28--0.32\]      0.30 \[0.29--0.34\]      0.862
  Lumen area, mm^-2^x10^-3^                                    18.0 \[12.9--23.4\][^‡^](#t002fn003){ref-type="table-fn"}   27.9 \[25.3--37.3\]      26.9 \[16.9--35.4\]      0.013
  Intima area, mm^-2^x10^-3^                                   24.0 \[18.2--32.7\]                                         21.2 \[16.4--33.3\]      15.4 \[12.2--21.1\]      0.092
  Muscular area, mm^-2^x10^-3^                                 21.8 \[17.0--34.9\]                                         27.5 \[21.1--45.4\]      30.3 \[26.5--33.8\]      0.291
  **Severity Indices**[^b^](#t002fn005){ref-type="table-fn"}                                                                                                                 
  \% intimal area                                              37.3 ± 2.2^†,^[^‡^](#t002fn003){ref-type="table-fn"}        29.3 ± 2.3               23.6 ± 2.8               0.002
  \% luminal narrowing                                         56.1 ± 3.1^†,^[^‡^](#t002fn003){ref-type="table-fn"}        43.4 ± 3.2               37.9 ± 4.1               0.003
  Intimal thickness index                                      0.99 ± 0.06^†^                                              0.82 ± 0.06              0.54 ± 0.08              \<0.001
  Intima to media ratio                                        1.17 ± 0.10^†^                                              1.03 ± 0.11              0.80 ± 0.13              0.107
  ------------------------------------------------------------ ----------------------------------------------------------- ------------------------ ------------------------ --------------------

Data are presented as median \[IQR\] or LSM ± SEM. The reported p-value comes from the overall comparison with ANCOVA method with a general linear model using as covariables: gender, MetS, cHDL and circulating leukocytes.

Between-group comparisons were performed using the least significant difference method, where ^†^ means a p-value \<0.05 for the difference between COPD and non-smokers group, and

^‡^ means a p-value \<0.05 for the difference between COPD and smokers group.

^a^Index of narrowing is estimated as the ratio between the measured total area and that extrapolated from the theoretical distended diameter: \[*theoretical diameter = length of the external elastic lamina / pi (π)*\].

^b^The severity indices were calculated using the following formulas: % intimal area = 100 X intimal area/measured total area (area encompassed by the external elastic lamina); % luminal narrowing = 100 X intimal area/internal elastic lamina area; Intimal thickness index = intimal area/medial area; and Intima to media ratio = width of intima at maximal intimal thickness/width of media at maximal intimal thickness.

In muscular pulmonary arteries, the morphometric valuation revealed similar vessel dimensions among groups ([Table 2](#pone.0152987.t002){ref-type="table"}). However, it was observed that two of the intimal thickening parameters (%IA and %LN) were significantly higher in the COPD group than in the smokers group. Furthermore, each of the 4 severity indices was significantly superior in the COPD group compared to the non-smokers group. In addition, a greater degree of intimal thickening (ITI) was observed in the smokers group compared to the non-smokers group. It is noteworthy that the only clinical factor associated with the %IA of pulmonary vessels in the regression analysis was COPD status. Therefore, the data reported above are from the unadjusted analysis. Plots of individual data for intimal thickening of pulmonary arteries by groups are represented in [Fig 2E--2H](#pone.0152987.g002){ref-type="fig"}. There was agreement in morphometric measurements between the two observers with an intra-class correlation coefficient (ICC) of 0.907 (CI from 0.78 to 0.96, p\<0001).

Factors associated with intimal thickening in systemic and pulmonary arteries {#sec014}
-----------------------------------------------------------------------------

The results of univariate and multivariate regression analyses of the factors associated with intimal thickening in systemic arteries (%IA) are summarized in [Table 3](#pone.0152987.t003){ref-type="table"}. Based on these results, five variables were identified (p\<0.10) as possible risk factors: male gender, leukocytes count and cHDL (related to lower %IA) and MetS and COPD (related to higher %IA). In the analyses explained above, the presence of Diabetes Mellitus and the pack-years were not associated to %IA ([Table 3](#pone.0152987.t003){ref-type="table"}). In the multivariate analysis, only MetS, gender and COPD were significantly associated with %IA. [Table 4](#pone.0152987.t004){ref-type="table"} shows the clinical variables tested as possible factors associated with pulmonary intimal thickening (%IA). Only COPD was significantly associated with %IA.

10.1371/journal.pone.0152987.t003

###### Linear regression analyses for associations between clinical variables and the intimal thickening (%IA) of systemic arteries in the overall population.

![](pone.0152987.t003){#pone.0152987.t003g}

  Dependent variable:% Intimal area   Univariateβ coefficient \[95% CI\]   p-value   Multivariateβ coefficient \[95% CI\]   p-value
  ----------------------------------- ------------------------------------ --------- -------------------------------------- ---------
  Male gender                         -6.33 \[11.20- -1.46\]               0.013     -6.64 \[-11.14- -2.14\]                0.005
  Age                                 0.061 \[-0.14--0.26\]                0.543                                            
  BMI                                 0.15 \[-0.35--0.64\]                 0.541                                            
  Pack-years                          -0.03 \[-0.21--0.16\]                0.758                                            
  Emphysema                           0.173 \[-6.85--7.20\]                0.960                                            
  Systemic hypertension               -1.31 \[-5.82--3.20\]                0.555                                            
  Diabetes Mellitus                   0.86 \[-6.13--7.84\]                 0.801                                            
  Metabolic syndrome                  5.78 \[1.84--9.73\]                  0.006     5.52 \[2.21--8.82\]                    0.002
  Lipid lowering                      1.48 \[-4.03--6.98\]                 0.585                                            
  ACEIs/ARBs                          -0.20 \[-8.65--8.25\]                0.961                                            
  cHDL                                -3.59 \[-7.79--0.60\]                0.091     -3.32 \[-7.10--0.45\]                  0.083
  cLDL                                0.62 \[-1.81--3.14\]                 0.618                                            
  Triglycerides                       -1.24 \[-4.71--2.24\]                0.471                                            
  Leukocytes                          -0.89 \[-1.94--0.16\]                0.095     -0.64 \[-1.55--0.27\]                  0.164
  COPD                                4.78 \[0.53--9.03\]                  0.029     4.96 \[1.43--8.48\]                    0.007

BMI: body mass index, ACEIs/ARBs: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, cHDL: high-density lipoprotein cholesterol, cLDL: low-density lipoprotein cholesterol.

10.1371/journal.pone.0152987.t004

###### Linear regression analyses for associations between clinical variables and the intimal thickening (%IA) of pulmonary arteries in the overall population.

![](pone.0152987.t004){#pone.0152987.t004g}

  Dependent variable:% Intimal area   Univariateβ coefficient \[95% CI\]   p-value
  ----------------------------------- ------------------------------------ ---------
  Male gender                         -2.77 \[-11.78--6.25\]               0.530
  Age                                 0.109 \[-0.23--0.45\]                0.515
  BMI                                 -0.06 \[-1.09--0.97\]                0.902
  Pack-years                          0.09 \[-0.04--0.23\]                 0.163
  Emphysema                           -1.79 \[-9.83--6.24\]                0.647
  Systemic hypertension               -1.21 \[-12.65--10.23\]              0.827
  Diabetes Mellitus                   -4.61 \[-12.22--2.99\]               0.223
  Metabolic syndrome                  0.94 \[-9.01--10.89\]                0.844
  Lipid lowering                      3.37 \[-2.47--9.20\]                 0.247
  ACEIs/ARBs                          1.52 \[-8.16--11.19\]                0.746
  Inhaled CS                          4.32 \[-5.91--14.55\]                0.391
  Leukocytes                          -0.86 \[-2.38--0.65\]                0.252
  COPD                                10.23 \[4.37--16.09\]                0.001

BMI: body mass index, ACEIs/ARBs: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, CS: corticosteroids.

Correlations between systemic and pulmonary intimal thickening {#sec015}
--------------------------------------------------------------

Significant correlations were observed in the %IA between systemic and pulmonary arteries (Spearman's rho = 0.435, p = 0.016) in the overall population. However no correlation was observed between systemic and pulmonary arteries in %LN (Spearman's rho = 0.360, p = 0.051), ITI (Spearman's rho = 0.145, p = 0.445) and IMR (Spearman's rho = 0.061, p = 0.749). In [Fig 3](#pone.0152987.g003){ref-type="fig"}, microphotographs of systemic and muscular pulmonary arteries with ascending intimal thickening, belonging to the three groups of study are represented.

![Representative photomicrographs of orcein stained elastin fiber in cross sections of intercostal and muscular pulmonary arteries.\
Images from A to C represent intercostal arteries sections. The intima in **A** (COPD) is thicker than in the smokers (**B**) and the non-smokers (**C**) group. Images from D to F show the muscular pulmonary arteries sections of COPD (**D**), smokers (**E**), and non-smokers (**F**). Vessel remodelling, characterized by thickening of the intima layer, is more evident in the COPD group. Elastin-orcein stain, scale bar = 100μm.](pone.0152987.g003){#pone.0152987.g003}

Discussion {#sec016}
==========

The present investigation is, to the best of our knowledge, the first histo-morphometric analysis performed with the aim of evaluating concomitantly the intimal thickening of the systemic and pulmonary arteries of COPD subjects compared to smokers. The principal findings of this study can be summarized as follows: 1) Patients with COPD have an increased %IA of systemic and pulmonary arteries compared to smokers with normal lung function; 2) %IA of systemic arteries is independently related to gender, the presence of metabolic syndrome and COPD, while the %IA of pulmonary arteries is related only with COPD; 3) there is a correlation between the %IA of systemic and pulmonary arteries in the overall population.

Previous studies have shown that the intimal thickening of systemic arteries is due to the increased formation of extracellular matrix (ECM), which includes an increased secretion and deposition of proteins, growth factors and enzymes that regulate ECM.\[[@pone.0152987.ref014]\] These remodeling changes could contribute to different clinical vascular disorders such as multifactorial atherosclerosis.\[[@pone.0152987.ref015]\] In the context of the current study, four methods were used to evaluate the propensity of in situ IC artery and muscular pulmonary arteries to develop intimal thickening: %IA, %LN, ITI and IMR. The %IA, %LN and ITI indices are measures of the severity of intimal thickening that allow for an accurate evaluation of eccentric or irregular disease since they consider areas rather than widths. Also, they could be useful for comparing intimal thickening between different vascular beds.\[[@pone.0152987.ref012]\] IMR is an alternative method for comparing intimal disease, and it specifically evaluates the severity of atherosclerosis, in which the maximal thickness of intima from cross sectional is considered and is presumed to be a useful parameter for comparisons of the same artery among different patients but cannot be used to compare different vascular beds.\[[@pone.0152987.ref012]\] In the present study, it was found that COPD subjects exhibit an increased intimal thickening of systemic arteries in terms of %IA and a numerically increasing trend in terms of %LN and ITI compared to smokers; all three of these parameters are area-dependent. Nonetheless, no differences were found in IMR, which could be explained by the irregular intimal thickening observed. Overall, these results support the idea that COPD patients exhibit a major intimal hyperplasia in systemic circulation compared to smokers with normal lung function. This novel data is of particular relevance since these vascular changes could be the initial lesions in a complex process resulting in atherosclerosis or the beginning of a non-atherosclerosis related subclinical vascular disease.\[[@pone.0152987.ref016]\] In line with this, prior studies using different non-invasive measurements to evaluate subclinical vascular disease determined an increased cardiovascular risk in stable COPD subjects independent of age or smoking status.\[[@pone.0152987.ref017]--[@pone.0152987.ref020]\] Specifically, the ultrasonographic evaluation of vascular remodelling showed that carotid artery wall thickening (carotid intima-media thickness) was associated with the severity of airflow limitation in COPD subjects.\[[@pone.0152987.ref017]--[@pone.0152987.ref020]\] Similarly, there are data supporting the association of more advanced vascular disease in elderly subjects with COPD, assessed by high-resolution magnetic resonance imaging, where COPD was an independent predictor for the presence of a lipid core, and therefore of vulnerable plaque in the carotid artery.\[[@pone.0152987.ref017]\] Of note, the current analysis of IC arteries of the non-smoker and smoker group show a similar intimal layer as in morphometric studies in post-mortem subjects who had died of non-cardiac diseases,\[[@pone.0152987.ref021]\] which gives consistence to our results.

Most of the studies focussing on atherosclerosis have been performed in arterial tissue from arterectomies or are post-mortem studies carried out in advanced stages of the disease.\[[@pone.0152987.ref021]\] However, a valid alternative to studying the initial processes is the evaluation of the 5^th^ IC artery which arises from the descending thoracic aorta and provides blood supply to the ribs, IC spaces and skin of the anterolateral thoracic wall.\[[@pone.0152987.ref022]\] Of all IC arteries, the 5^th^ IC artery has the greatest luminal diameter, length and rate of flow,\[[@pone.0152987.ref023]\] which makes it accessible in all patients undergoing open thoracotomy. Also, of the three segments of the IC artery: proximal, middle and distal, the middle level (analyzed in this study), has a thin inner layer and a muscular or elasto-muscular media layer, characterized by an absence or by few elastic laminas except for the IEL and EEL, respectively.\[[@pone.0152987.ref021]\] These two features result in a greater tendency toward intimal hyperplasia as compared to elastic conduits,\[[@pone.0152987.ref013],[@pone.0152987.ref015]\] therefore muscular IC artery appears histologically more in the coronary arteries or radial arteries, where remodelling is most evident.\[[@pone.0152987.ref015],[@pone.0152987.ref021],[@pone.0152987.ref023]\]

Risk factors for the intimal thickening of systemic arteries vary widely between morphometric studies; in general the clinical variables tested are the same ones that are related to clinical atherosclerosis. However, previous studies have demonstrated that different arterial beds have different risk factors for the development of intimal hyperplasia and atherosclerosis.\[[@pone.0152987.ref013]\] The most common clinical factors associated with intimal hyperplasia in different arteries (non IC artery), as measured by different methods are: diabetes mellitus, renal failure, hypertension, peripheral vascular disease, smoking and age.\[[@pone.0152987.ref013]\] In our study, the factors associated with the intimal thickening of the IC artery as measured by %IA were female gender, metabolic syndrome and COPD status. Although female gender may have different features in the functional and morphometric behavior of systemic arteries, as previously reported;\[[@pone.0152987.ref024]\] in our study, the poor representation of women in some of the groups analyzed makes the interpretation of results difficult, as we discussed in the limitations section. In pulmonary circulation, the results of an increased intimal thickening of the muscular pulmonary arteries of COPD subjects are in agreement with prior morphometric studies that have demonstrated a higher proliferation of smooth muscles cells and the deposition of ECM proteins in the intima layer of the pulmonary vessels in COPD subjects.\[[@pone.0152987.ref007],[@pone.0152987.ref025]\]

Another novel issue in this study is the relationship between systemic and pulmonary vascular remodeling changes assessed by histo-morphometric analysis. Previous studies evaluating pulmonary vascular disease (measured by the cross sectional area of small pulmonary vessels in computerized tomography) or histological pulmonary atherosclerosis (in post-mortem analysis) showed a positive correlation with the atherosclerosis of systemic arteries.\[[@pone.0152987.ref026]--[@pone.0152987.ref027]\] Although the underlying mechanisms are still unknown, it is hypothesized, that systemic inflammation and endothelial dysfunction may promote both systemic and pulmonary vascular alterations, and may lie behind the close relationship between both conditions.\[[@pone.0152987.ref028]\] As previously reported in systemic sclerosis, an immunologic disorder with a simultaneous impairment of systemic and pulmonary circulation could occur.\[[@pone.0152987.ref029]\]

Limitations {#sec017}
-----------

The principal limitation of the study is the poor representation of female gender in the COPD and smokers groups due to the baseline characteristics of our population (patients with lung carcinoma and a major smoking habit are mostly male patients). Therefore, this gender misbalance makes it difficult to draw conclusions about gender beyond spurious associations. The population of the study has primary, treatable lung cancer; therefore lung cancer could be a possible introduced bias. However, we are assuming any effect would be the same across all the subjects included in the study. It is important to consider that it would be impossible to obtain lung tissue and arterial samples from living patients, if it were not for the indication of the surgery. Another possible limitation of the study is that, due to its observational design, causal conclusions or strong conclusions cannot be drawn beyond observing a significant association between the presence of COPD and vascular remodelling changes in systemic and pulmonary arteries.

Conclusions {#sec018}
-----------

In conclusion, the current study shows a greater intimal thickening in systemic and pulmonary arteries in the COPD group compared to smokers group. These histopathological observations imply that subjects with a mild-moderate COPD in addition to pulmonary vascular involvement, also show systemic vascular changes (histological remodelling) which could explain the high prevalence of cardiovascular disease in COPD patients. Therefore, in clinical practice, the adequate management of pulmonary disease and others modifiable cardiovascular risk factors should be a target in all subjects with COPD, even in mild stages, in order to minimize cardiovascular consequences. The present study provides a model for future studies involving initial remodelling changes in both systemic and pulmonary circulations.

Supporting Information {#sec019}
======================

###### Additional definitions and details of analyses.

(DOCX)

###### 

Click here for additional data file.
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